Moreover, flubendazole exhibits anticarcinoma effects in triple-negative breast carcinoma by targeting EVA1A-modulated autophagy and apoptosis (Zhen et al., 2020). This evidence concerns the gene EVA1A and triple-negative breast carcinoma.